Pharmalittle: Gilead poaches Roche’s CEO; state prosecutors widen generics probe

first_img About the Author Reprints Pharmalittle: Gilead poaches Roche’s CEO; state prosecutors widen generics probe Ed Silverman By Ed Silverman Dec. 10, 2018 Reprints Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, because that oh-so-familiar routine of meetings, deadlines, phone calls, and memos has returned. Did we forget something? The world, after all, keeps on spinning. To attain some equilibrium, yes, we are firing up the coffee kettle for a few cups of stimulation. Our choice today is a blend of cranberry and white chocolate. Meanwhile, here are some tidbits to help you get started. Hope your day is wonderful and productive. And of course, do keep in touch …Gilead Sciences (GILD) hired Roche (RHHBY) chief executive Daniel O’Day to run the company amid pressure to revive sales as its hepatitis C franchise declines and to recover from a disappointing deal for a CAR-T treatment, The Wall Street Journal reports. Sales of the Yescarta CAR-T medicine have so far been meager, while O’Day has a record turning drugs into big sellers. For this reason, O’Day, who replaces John Milligan on March 1, should be viewed favorably by Gilead investors, according to STAT. Roche, meanwhile, elevated Bill Anderson, who heads the Genentech unit, to oversee its pharma business. What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.center_img [email protected] @Pharmalot Pharmalot Alex Hogan/STAT GET STARTED Log In | Learn More What’s included? Tags drug pricingpharmaceuticalspharmalittleSTAT+last_img


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top